Company intelligence / Profile preview

Imgen BioSciences

Fall River, Massachusetts, United Statesimgenbiosciences.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Imgen BioSciences is developing immunotherapeutic agents and techniques, with a focus on novel TCR-CAR-T technologies for cancer and infectious disease. The company has been granted patents related to CAR-T and TCR-CAR-T platforms but has not publicly disclosed results from human clinical trials.

Therapeutic areas: Infectious DiseasesOncology
Modalities: CAR-T cell therapyImmunotherapy (general)
Industry: Biotech

Drug pipeline

1 asset

Tcar-T

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Imgen BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imgen BioSciences.

Explore the full profile